The choline phospholipid metabolism as clinical biomarker and potential target of breast cancer
- Prosjektnummer
- 46056617
- Ansvarlig person
- Maria Dung Cao
- Institusjon
- NTNU, ISB
- Prosjektkategori
- Postdoc-stipend 2012
- Helsekategori
- Cancer
- Forskningsaktivitet
- 6. Treatment Evaluation
Phospholipase D1 and choline kinase-a are interactive targets in breast cancer.
Cancer Biol Ther 2014 May;15(5):593-601. Epub 2014 feb 20
PMID: 24556997
Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.
NMR Biomed 2014 Jun;27(6):692-9. Epub 2014 apr 24
PMID: 24764256
Metabolic characterization of triple negative breast cancer.
BMC Cancer 2014;14():941. Epub 2014 des 12
PMID: 25495193
Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
NMR Biomed 2012 Feb;25(2):369-78. Epub 2011 aug 8
PMID: 21823183
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
BMC Cancer 2012;12():39. Epub 2012 jan 25
PMID: 22277092
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
NMR Biomed 2012 Sep;25(9):1033-42. Epub 2012 jan 26
PMID: 22279038
Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer.
Proc Natl Acad Sci U S A 2012 Sep;109(38):E2506; author reply E2507. Epub 2012 jul 31
PMID: 22851771
Metabolic characterization of triple negative breast cancer.
Joint annual meeting ISMRM-ESMRMB 2014
Behandling av aggressiv brystkreft- finnes svaret i våre metabolitter?
NTNU Blogg
Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decreases breast cancer cell proliferation and invasion
ISMRM 2014
Methylation, metabolomics and response
Kongsvold møte 2014
The potential and challenges of HR MAS MRS in characterization of breast cancer
ISMRM Cancer Workshop 2014
Prediksjon av behandlingsrespons og overlevelse i pasienter med lokalavansert brystkreft.
BestPractice Onkologi/Hematologi 2012 (8)
Metabolomics of cancer tissue.
Internundervisning; 2012-10-18 - 2012-10-18 NTNU/St.Olav
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
Muntlig presentasjon Kongsvold møte; 2012-08-29 - 2012-08-30 Kongsvold
Metabolic response to glycerophosphocholine phosphodiesterase GDPD5 silencing in human breast cancer cells.
Poster presentasjon Personalized cancer care 2012; 2012-09-07 - 2012-09-09 Oslo
Metabolic response to glycerophosphocholine phosphodiesterase GDPD5 silencing in human breast cancer cells.
Poster presentasjon Metabomeeting 2012; 2012-09-25 - 2012-09-27 Manchester
siRNA-mediated silencing of the glycerophosphocholine phosphodiesterase GDPD5 in breast cancer cells.
Poster presentasjon Opening of MR Core Facility; 2012-10-23 - 2012-10-23 NTNU
siRNA-mediated silencing of the glycerophosphocholine phosphodiesterase GDPD5 in breast cancer cells.
Poster presentasjon Regional forskningskonferanse HMN 2012; 2012-06-05 - 2012-06-06 Trondheim
siRNA-mediated silencing of the glycerophosphocholine phosphodiesterase GDPD5 in breast cancer cells.
Poster presentasjon ISMRM annual scientific meeting 2012; 2012-05-05 - 2012-05-11
Magnetic Resonance Spectroscopy study on the effects of stably silencing the glycerophosphocholine phosphodiesterase GDPD5 in a
Muntlig presentasjon ISMRM annual scientific meeting 2012; 2012-05-05 - 2012-05-11 Melbourne
MR metabolic characterization of locally advanced breast cancer - treatment effects and prognosis
- Disputert:
- mars 2012
- Hovedveileder:
- Ingrid S Gribbestad
- Tone Frost Bathen Prosjektleder
- Maria Dung Cao Postdoktorstipendiat
- Ulrik Wisløff Hovedveileder
- Øivind Rognmo Medveileder, biveileder
- Gjertrud Aunet Tyldum Doktorgradsstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Helse Midt-Norge RHF - Samarbeidsorganet og FFU